According to our (Global Info Research) latest study, the global Capmatinib Hydrochloride Tablets market size was valued at US$ 185 million in 2025 and is forecast to a readjusted size of US$ 1195 million by 2032 with a CAGR of 12.6% during review period.
In 2025, global Capmatinib Hydrochloride Tablets production reached approximately 180,000 units.Capmatinib Hydrochloride Tablets are a highly selective mesenchymal–epithelial transition (MET) receptor tyrosine kinase inhibitor and belong to small-molecule oral targeted anticancer drugs. They primarily act by inhibiting the abnormal activation of the MET signaling pathway, thereby blocking tumor cell proliferation, migration, and survival, and play an important role in precision oncology. This drug is mainly used for the treatment of patients with non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations. It is characterized by strong target specificity, proven efficacy, and convenient oral administration, and represents an important therapeutic option in the field of MET-targeted therapies.
Capmatinib Hydrochloride Tablets, as a precision targeted anticancer drug acting on the MET signaling pathway, occupy an important position in the segmented treatment market for non-small cell lung cancer (NSCLC). With the increasing adoption of genetic testing and improved identification of patients with MET exon 14 skipping mutations, the target patient population is gradually expanding, driving steady growth in market demand. Meanwhile, under the trend of precision medicine and personalized therapy, the clinical value of MET inhibitors continues to become more prominent. However, market competition is also intensifying, including from similar MET inhibitors such as Tepotinib as well as other targeted therapies, which pose certain pressures on its market share. Overall, the market for Capmatinib Hydrochloride Tablets represents a “high-value, small-population” niche, with future growth mainly driven by increased diagnostic penetration, expansion of indications, and global market development.
This report is a detailed and comprehensive analysis for global Capmatinib Hydrochloride Tablets market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Capmatinib Hydrochloride Tablets market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Capmatinib Hydrochloride Tablets market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Capmatinib Hydrochloride Tablets market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Capmatinib Hydrochloride Tablets market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Capmatinib Hydrochloride Tablets
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Capmatinib Hydrochloride Tablets market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Incyte, Sinoway Industrial, Simson Pharma Limited, Hangzhou Jinlan Pharm-Drugs Technology, Dingwang Technology, Beijing SJAR Technology Development, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Capmatinib Hydrochloride Tablets market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Genetically Mutated Population
Advanced or Metastatic Patients
Market segment by Specification
150 mg/Tablet
200 mg/Tablet
Market segment by Production Technology
Innovator
Originator
Market segment by Dosage Form
Tablet
Film-coated Tablet
Market segment by Application
Non-Small Cell Lung Cancer (NSCLC)
MET Exon 14 Skipping Mutation-Positive Patients
Advanced or Metastatic Lung Cancer
Others
Major players covered
Novartis
Incyte
Sinoway Industrial
Simson Pharma Limited
Hangzhou Jinlan Pharm-Drugs Technology
Dingwang Technology
Beijing SJAR Technology Development
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Capmatinib Hydrochloride Tablets product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Capmatinib Hydrochloride Tablets, with price, sales quantity, revenue, and global market share of Capmatinib Hydrochloride Tablets from 2021 to 2026.
Chapter 3, the Capmatinib Hydrochloride Tablets competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Capmatinib Hydrochloride Tablets breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Capmatinib Hydrochloride Tablets market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Capmatinib Hydrochloride Tablets.
Chapter 14 and 15, to describe Capmatinib Hydrochloride Tablets sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Capmatinib Hydrochloride Tablets. Industry analysis & Market Report on Capmatinib Hydrochloride Tablets is a syndicated market report, published as Global Capmatinib Hydrochloride Tablets Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Capmatinib Hydrochloride Tablets market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.